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Abstract: Levodopa is the most effective treatment in Parkinson’s disease and the association 
with COMT inhibitors widens its plasma bioavailability and effectiveness. Tolcapone is a 
potent COMT inhibitor whose utilization in PD is limited due to safety concerns on liver tox-
icity. However, recent data indicate that if liver function is actively monitored, tolerability is 
no worse than other currently available therapies. By contrast, administration of tolcapone is 
associated with signiﬁ  cant clinical improvement and beneﬁ  t involves also non-motor features. 
In this review we discuss the rationale for the use of tolcapone in association with levodopa and 
other treatments in PD, and we provide an indirect comparison of current strategies to reduce 
“off” time. We propose that future guidelines include a trial with tolcapone in all PD patients 
who continue to complain about motor ﬂ  uctuations despite treatment with entacapone and/or 
MAO-B inhibitors. Moreover, we suggest that tolcapone should be considered before surgical 
or infusional strategies are applied.
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Introduction
Management of motor ﬂ  uctuations and dyskinesias is still a major challenge in the 
long-term treatment of patients with Parkinson’s disease (PD) as they affect daily life 
activities and in turn quality of life of patients and caregivers. Symptoms associated 
with the “off phase” not only include akinesia, rigidity, and tremor, but also depression, 
anxiety or even panic attacks (Lauterbach 2005). In the advanced stages of the disease 
both motor and non-motor ﬂ  uctuations are present (Nutt and Holford 1996).
Dyskinesias are classified according to their temporal profile after drug 
administration, namely peak-dose dyskinesias (mainly choreic movements), biphasic 
dyskinesias, onset and end-of-dose (mainly dystonic and ballic movements), and ﬁ  nally 
“off”-period dyskinesias (dystonic movements) (Defebvre 2004).
In general motor ﬂ  uctuations and dyskinesia develop in about 10% of patients per 
year after starting levodopa treatment, reaching almost 100% of patients after 10 years’ 
treatment (Marsden and Parkes 1997; Van Laar 2003). The DATATOP study reported 
high rates of motor ﬂ  uctuations and dyskinesias (PSG 1996), but this might be related 
to direct patient observation during the trial phase (Lang and Lozano 1998).
Recently, a retrospective analysis of the CALM-PD study reported an incidence of 
motor ﬂ  uctuations within a range from 12% to 60%, and an incidence of dyskinesias 
from 8% to 64%, after 4–6 years of levodopa therapy (Hauser et al 2006).
Factors involved in the development of motor complications are not completely 
elucidated yet. Patients with motor ﬂ  uctuations (wearing off, on-off phenomenon) 
may show akinetic-rigid onset, longer disease and treatment duration, higher intake 
of levodopa dose per day ( 300 mg/day), and occasionally longer time latency since Neuropsychiatric Disease and Treatment 2008:4(1) 2
Antonini et al
diagnosis. They also show greater disability according to 
the Schwab-England scale and disease severity. The ﬁ  nding 
of a family history of parkinsonism is also frequent, sug-
gests that positive genetic may lead to greater propensity 
to development of motor complications. Similarly patients 
with dyskinesias tend to present higher Hoehn and Yahr 
score and longer treatment duration, while association with 
levodopa daily dose is less consistent. Gender as well as 
genetic factors related to dopamine D2 receptor gene may 
also play an important role and contribute to development 
of peak-dose dyskinesia in women (Schrag and Quinn 2000; 
Zappia et al 2005).
Although fluctuations in response to levodopa are 
typically deﬁ  ned by changes in motor signs, autonomic and 
psychological ﬂ  uctuations may also occur.
Non-motor ﬂ  uctuations (NMF) are extremely disabling 
for PD patients; they affect activity of daily living and qual-
ity of life and have recently received growing attention by 
movement disorders experts. Similar to motor ﬂ  uctuation, 
non-motor ﬂ  uctuations also tend to increase with disease 
progression, and are more disabling in younger patients 
(Riley and Lang 1993; Witjas et al 2000).
Non-motor ﬂ  uctuations may involve cognitive, psychi-
atric, sensory/pain, and autonomic domains (Chaudhuri et al 
2006, 2007).
Assessment of frequency and disability caused by NMF 
was evaluated in 50 PD patients by the administration of 
a speciﬁ  c questionnaire (Maricle et al 1998). All patients 
showed at least one type of NMF, mostly associated with 
the “off” state. The most represented were anxiety (66%), 
drenching sweats (64%), slowness of thinking (58%), fatigue 
(56%), and akathisia (54%). All NMF contributed to the 
worsening motor disability, and especially fluctuations 
linked to autonomic functions were also related to levodopa 
treatment.
Some degree of sadness and mood switching is also fre-
quently reported during “on-off” periods (Martinez-Martin 
et al 2007). Mood ﬂ  uctuations may occur more frequently 
in patients with involvement of cortical or mesolimbic areas 
(Chaudhuri et al 2006).
The stringent relationship between levodopa response and 
non-motor ﬂ  uctuations is also supported by the occurrence 
of “off period” depressive symptoms after discontinuation of 
levodopa intravenous infusion (Maricle et al 1995, 1998).
Finally, a PET study in a small number of PD patients 
showed that rCBF response to levodopa in medial frontal 
gyrus and posterior cingulated cortex (PCC), was different 
between mood ﬂ  uctuators and controls (Black et al 2005). As 
PCC is strongly linked to emotions and mood, and it is known 
to modulate dopaminergic innervations of caudate nucleus, 
anterior cingulated cortex, and orbital frontex, the authors 
speculate that mood ﬂ  uctuations in PD might be related to 
dysfunction in levodopa responsiveness.
Levodopa administration 
and response to levodopa: addressing 
indication to starting therapy
Levodopa is the most effective treatment of PD cardinal 
symptoms (rigidity, akinesia, tremor, postural instability) 
(Rascol et al 2002). The onset of effect is rapid, and 
most clinical trial results suggest that initiating treatment 
provides superior motor and functional control compared 
with other dopaminergic substances. Levodopa is generally 
well tolerated, with lower incidence of gastrointestinal and 
neuropsychiatric adverse events (Halkias et al 2007).
The mechanism of action is not simply characterized by 
a central conversion of levodopa to dopamine at surviving 
dopaminergic terminals, but also by a neuromodulation 
(Opacka-Juffry and Brooks 1995), and likely internalization 
of D1 receptors, as demonstrated in rats (Muriel et al 2002). 
Moreover, increasing motor ﬂ  uctuations in the afternoon and 
evening in patients during long-term levodopa therapy may 
not relate to the pharmacokinetics of the drug but express 
tolerance to repeated doses of levodopa (Bonuccelli et al 
2000).
Administration of levodopa is associated with negative 
perception on motor complications risk, leading to a delay 
in initiating treatment that has been deﬁ  ned as “levodopa 
phobia”.
The relevance of patient age at disease onset for start-
ing levodopa therapy is still debated and current guidelines 
have not yet properly assessed this issue. The problem of 
starting levodopa treatment early arises in younger patients 
with mild motor dysfunction, in consideration of life 
expectancy and disease progression. Because of its greater 
efﬁ  cacy than dopamine agonists, levodopa is recommended 
as ﬁ  rst-line agent always in case of a rapid and sustained 
worsening of motor symptoms, regardless of age (Olanow 
et al 2001).
The declining efﬁ  cacy of levodopa therapy surely recog-
nizes, at least in part, a progression of the disease, and this 
must be considered especially in terms of expectations on 
quality of life.
Some hypotheses around the mechanisms by which 
response ﬂ  uctuations may occur with levodopa have been 
conceived (Van Laar 2003):Neuropsychiatric Disease and Treatment 2008:4(1) 3
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1)  presynaptic neuronal degeneration leading to insufﬁ  cient 
buffering of released levodopa, which could be mainly 
related to the “wearing off” phenomenon.
2)  postsynaptic changes in dopamine receptor sensitivity and 
number, partially caused by presynaptic changes , which 
could be related to the unpredictable ﬂ  uctuations.
3) pharmacokinetic and pharmacodynamic inﬂ  uence of 
other dopaminergic agents or non-pharmacological 
agents (such as food).
Clinical response to levodopa can identify 
at least three different mechanisms
The best known is the short-duration response (SDR), 
measured in minutes to hours, with a steep concentration – 
response relationship such that the response appears “all or 
nothing”. The duration of the effect is dose-responsive. During 
chronic therapy, the SDR becomes shorter, as does the onset 
to effect, whereas the magnitude of the response becomes 
larger, probably because of a sensitization phenomenon (Nutt 
1995). With regard to tolerance, experiments on levodopa 
holidays of 2–4 days, demonstrated that post-holiday infusion 
produced a longer response than did pre-holiday infusion, 
as measured by tapping and walking speed, tremor, and 
dyskinesias. The prolongation of the response was greater 
in patients receiving higher daily doses of levodopa (Nutt 
et al 1994).
The long-duration response (LDR) results from repetitive 
administrations of levodopa and develops over days or weeks 
after starting treatment (Zappia et al 1999a). It is independent 
of single intakes of levodopa which, in turn, determine SDRs 
associated with motor ﬂ  uctuations and dyskinesia (Zappia et al 
1997). On the contrary, the presence of the LDR may ensure a 
stable clinical beneﬁ  t and its disappearance may be relevant for 
the development of a ﬂ  uctuating condition (Zappia et al 1999b). 
The LDR is more evident in early PD stages, but it could be 
induced also in more advanced stages (Quattrone et al 1995), 
by modulating the inter-dose intervals and the size of each 
dose (Zappia et al 2000).The rate of decay is proportional to 
the severity of illness, and therefore it might be related to the 
dopamine storage capacity of surviving nerve terminals. Finally 
in advanced stages of the disease, we can also identify a negative 
response (super-off), measured in minutes to hours, and consist-
ing of motor function worsening below the basal level.
Strategies to widen levodopa 
therapeutic window
The management of motor and non-motor ﬂ  uctuations aims 
at prolonging the effect of dopaminergic stimulation possibly 
reducing total levodopa load. The effects of a single dose of 
levodopa may shorten to less than 2–3 hours in advanced 
patients. Early symptoms of “wearing off” may be improved 
by redistributing levodopa dosing during the day and shorten-
ing the interval between doses (Widnell and Cornella 2005). 
Alternatively, as modiﬁ  cations of LDR may underline motor 
ﬂ  uctuations (Zappia et al 1999a, b), strategies that involve 
increasing single levodopa dose rather than number of 
administrations might also be beneﬁ  cial, if dyskinesia does 
not worsen (Zappia et al 2000).
There are different strategies aimed at stimulating 
dopamine receptors in a more continuous, less pulsatile 
manner, to slow levodopa metabolism, interacting at dif-
ferent levels, and consequently providing a more sustained 
central effect.
Continuous intraduodenal infusion produces stable levo-
dopa plasma levels resulting in few off periods and dyskinesia 
as well as improved quality of life, but it can be applied only 
in limited cases (Antonini et al 2007).
Slow-release preparations of levodopa (Sinemet 
CR®, Madopar HBS®), associated with peripheral dopa 
decarboxylase inhibitor (DDCI), may be helpful in smoothing 
out fluctuations, alleviating tremor and rigidity during 
the night, and morning akinesia as well. However, their 
absorption and effect is often erratic making their use in a 
clinical setting very limited.
The MAO-B inhibitors: effectiveness 
and rationale for use in clinical setting
MAO-B inhibitors (selegiline, rasagiline), may be an 
alternative to levodopa in the early treatment (Goetz et al 
2005). Although no medication has been proven to slow the 
progression of the disease, preclinical studies have demon-
strated some neuroprotective effects of MAO-B blockers in 
animal experimental models. These drugs are generally well 
tolerated, although some concerns have been expressed with 
selegiline regarding cardiovascular effects (Lees 2005).
Three recent level 1 studies have provided new data on 
MAO-B rationale for clinical use. In 473 untreated early 
PD patients allocated to treatment with dopamine agonists 
(bromocriptine and lisuride), or to selegiline (Caraceni and 
Musicco 2001), the authors found that the lower frequency 
of motor complications in patients assigned to selegiline 
was not statistically signiﬁ  cant after a multivariate analysis 
including effects of age, disease duration, and baseline 
severity scores.
Shoulson et al (2002) performed an independent ran-
domization of 368 patients from the DATATOP original Neuropsychiatric Disease and Treatment 2008:4(1) 4
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cohort, who had been treated with selegiline and thereafter 
required levodopa, continuing with selegiline or switching 
to placebo under double-blind conditions. Patients were 
followed for 2 years, and primary outcome was the time to 
the ﬁ  rst development of “wearing-off” “on-off” ﬂ  uctuations, 
dyskinesia and freezing of gait; confusion and dementia 
were included in the analysis as well. The frequency of new 
occurrence in any primary variables was not signiﬁ  cantly 
different between the two arms.
Rasagiline, a second-generation, selective, reversible 
MAO-B inhibitor, is associated with beneﬁ  t in patients 
with early disease stage and reduced “off” time in patients 
with motor ﬂ  uctuations (Oldﬁ  eld et al 2007). According 
to the TEMPO study (PSG 2002), rasagiline is beneﬁ  cial 
as monotherapy in the early stage of the disease. Similar 
beneﬁ  t was reported in the LARGO study that compared 
the effect of entacapone and rasagiline in advanced PD 
(Rascol et al 2005). Interestingly, a significant mean 
reduction in “off” time was reported only in patients with 
mild to moderate dyskinesia but no advantage compared 
to placebo was found in the most severe advanced PD 
cohort. These ﬁ  ndings conﬁ  rm the difﬁ  culties that current 
strategies encounter in the management of this speciﬁ  c 
group of patients.
COMT inhibition with entacapone 
and tolcapone
Association of DDCIs with levodopa increases its metabo-
lism by catechol-O-methyltransferase to 3-O-methyl-dopa 
(3-OMD), in organs expressing COMT activity, such as liver, 
kidney, and gastrointestinal tract.
The 3-OMD metabolite has a long elimination half-life 
(approximately 15 hours), and may accumulate during 
long-term levodopa therapy. 3-OMD may compete with 
levodopa for passage across the BBB; moreover cerebral 
COMT metabolize levodopa to 3-OMD and dopamine to 
homovanillic acid (Kaakkola 2000). On the basis of this 
knowledge, the role of COMT inhibition seems crucial in 
PD therapy. Peripheral COMT inhibition reduces degrada-
tion of levodopa to 3-OMD, thus widening its therapeutic 
window, while a central COMT inhibition may further pro-
long levodopa effectiveness by reducing both levodopa and 
dopamine metabolism.
The new generation of COMT inhibitors entacapone and 
tolcapone are potent and selective and their role has become 
increasingly evident in the last decade (Figure 1).
The two drugs show a number of pharmacologic dif-
ferences and consequently, different clinical effectiveness. 
Tolcapone is a selective, reversible peripheral COMT 
inhibitor (Napolitano et al 1999). Activity on central COMT 
has also been demonstrated both clinically and with func-
tional imaging (Ceravolo et al 2002) and it can be observed 
for doses of 200 mg tid.
Data about efﬁ  cacy and safety of these drugs have been 
examined recently by a Cochrane review (Deane et al 2004). 
Comparing the efﬁ  cacy of the two COMT inhibitors across 
8 randomized controlled trials, tolcapone produced larger 
reductions in “off” time and levodopa requirements.
Tolerability proﬁ  le was similar; some of the reported 
adverse events were related to the increased availability of 
levodopa (nausea, vomiting, dyskinesias, hallucination), and 
ameliorated reducing levodopa dose. Some other adverse 
events were more strictly related to COMT-inhibition, in 
particular the occurrence of diarrhea.
Role of tolcapone in PD management
Tolcapone, a potent selective reversible COMT inhibitor, 
was launched in Europe in 1997, and in the US in 1998 
(Leegwater-Kim and Waters 2006). Its efﬁ  cacy as adjunct 
to levodopa therapy is attributed to the peripheral COMT 
inhibition, whereas there is still some debate around clini-
cal relevance associated to the central activity. Results of 
clinical trials conducted in PD patients, conﬁ  rm that tid 
administration of tolcapone magniﬁ  es levodopa motor ben-
eﬁ  t. Improvement had already been observed with a single 
200 mg dose (Napolitano et al 1999).
Compared with levodopa/DDCI alone, single or multiple 
doses of tolcapone 100 or 200 mg increased levodopa bio-
availability by 1.3 to 2.1 fold, both in healthy volunteers and 
in PD patients (Limousin et al 1995).
Pharmacological proﬁ  le of tolcapone is characterized 
by a greater bioavailability, and so has a greater area under 
the curve, Tmax and COMT enzyme afﬁ  nity, compared with 
entacapone. Tolcapone increases the levodopa half-life by 
80% versus 40% for entacapone, the levodopa area under 
the curve by 80% versus 40% for entacapone, providing a 
greater decrease in the formation of O-methyl-dopa as well 
(Factor et al 2001).
The results of a long-term comparative study between 
tolcapone and entacapone, suggest that tolcapone is more 
effective, and this difference in response would be predicted 
by the pharmacological differences between the two agents 
(Onofrj et al 2001). The study, performed in patients with 
ﬂ  uctuating PD, compared efﬁ  cacy and tolerability of tolca-
pone and entacapone, evaluating the effects prospectively 
at 6, 12, 24, and 36 months. Fourteen patients were enrolled Neuropsychiatric Disease and Treatment 2008:4(1) 5
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under tolcapone treatment, and eleven patients were enrolled 
under entacapone treatment. Tolcapone showed more effec-
tiveness in lowering UPDRS motor score and complication 
subscores, duration of “off” periods, and levodopa doses 
requirement (UPDRS motor score change was –5.07 ± 1.48 in 
tolcapone group, and +2.46 ± 2.76 for entacapone (p   0.02); 
duration of “off” period was –1 ± 0.23 for tolcapone, 0 ± 0.27 
for entacapone (p   0.03), lowering of L–DOPA dose was 
–400 ± 70.7 for tolcapone and +179.2 ± 160.8 for entacapone 
(p   0.04).
Another study in 40 patients with severe PD, with 
open design and direct switch-over from tolcapone 
to entacapone, was prompted because of mandatory 
indications of the European drugs authority, who withdrew 
tolcapone from market in November 1998. “On” time was 
increased by 15% during tolcapone treatment (p   0.05), 
and by 8% during entacapone treatment, whereas “off” 
time was decreased by 16% during tolcapone and by 7% 
during entacapone treatment. The reduction of L-DOPA 
was signiﬁ  cantly improved by tolcapone compared with 
entacapone (p = 0.05) (Lees et al 2007). IGA (Investigator 
Global Assessment) for wearing off severity, indicated that 
70–73% of the patients receiving tolcapone, and 56% of 
patients receiving entacapone, had a relevant improvement 
(p = 0.01).
A recent double blind study assessed patients receiving 
entacapone after random assignement to continue 
entacapone (n = 75) or switch to tolcapone (n = 75). The 
“on” time increased by  1 hour day in 43% of entacapone 
patients and in 53% of tolcapone patients and by  3 hours 
day in 13% and 25% of patients, respectively. The IGA 
indicated moderate/marked improvement in 25% of 
entacapone patients and 39% receiving tolcapone. No 
differences were observed in the rate of dyskinesias and 
adverse events leading to discontinuation of treatment 
(Pahwa et al 2006).
Safety and tolerability were evaluated with a focus 
on liver transaminase elevations and hepatotoxicity; 677 
levodopa-naïve patients were randomized to receive placebo 
or tolcapone as add-on therapy to standard doses of levodopa 
Periphery Brain
3-O-methyldopa
Levodopa
Dopamine
Carbidopa
AADC
Levodopa Dopamine
COMT
Tolcapone
Entacapone
AADC
Blood-brain barrier
Figure 1 COMT-I: mechanism of action.Neuropsychiatric Disease and Treatment 2008:4(1) 6
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(The Entacapone to Tolcapone Switch Study Investigators 
2007). Liver transaminase elevations above the upper normal 
limit (ULN) occurred in 20.2% and 27.5% of patients in the 
placebo and tolcapone groups, respectively. Elevations of 
ULN  3 fold occurred in 1.2% and 1.8% of placebo and 
tolcapone patients, respectively. No serious hepatotoxicity 
events were reported.
Efﬁ  cacy of oral tolcapone as adjunct therapy to levo-
dopa/DDCI, was demonstrated in several trials, although 
only in the short period (3 weeks’ to 3 months’ duration), 
both in ﬂ  uctuating and stable PD patients (Suchowersky 
et al 2001).
Clinical trials conducted in PD patients with motor 
fluctuations (wearing off, predictable “on-off”), were 
analyzed by a Committee of the American Academy of 
Neurology. The Committee recognized tolcapone is useful 
in reducing the “off” time, the need of levodopa daily dose, 
and prolonging the “on” phase.
Recently, also data from a comparator study (the 
SWITCH study) were presented. The aim of the study was 
to determine if switching from entacapone to tolcapone 
improves motor features. In the per-protocol analysis, 
a statistically signiﬁ  cant greater proportion of patients 
switched to tolcapone, had at least 3 hours/day of addi-
tional “on” time (p = 0.018). More patients on tolcapone 
were judged to have a moderate or marked improvement 
in the IGA, although not statistically signiﬁ  cant. Also the 
number of responders was higher on tolcapone, which 
appeared to have greater long-term beneﬁ  ts compared to 
entacapone (Table 1).
In patients with stable disease, tolcapone determines 
improvement from baseline in various end-points in a 
short-term study (Suchowersky et al 2001), showing an 
overall global improvement in 77% of patients at the IGA 
score, after 4 weeks double-blind treatment.
These preliminary results suggest potential beneﬁ  t on 
both motor and non-motor ﬂ  uctuations. In this respect, 
patient-perceived beneﬁ  t, obtained by smoother levodopa 
response, might be regarded also as an indirect effect of 
improved non-motor ﬂ  uctuations.
Table 1 Efﬁ  cacy of oral tolcapone 100 mg, entacapone, and rasagiline evaluated in terms of increasing hours of “on” time, decreasing 
hours of “off” time, and levodopa requirement
Study Study drug dosage 
(mg/tid)
Study 
duration
N of 
patients
Mean change from baseline:  Daily levodopa dosage:  
“on” time “off” time Baseline (mg/day) %change from b
Baas et al 1997 Tolcapone 100
Placebo
3 mo 60
58
 +1.7 h**
–0.1 h
–2 h*
–0.7 h 
667.5
660.5
–16*
–4
Rajput et al 1997  Tolcapone 100
Placebo
3 mo 69
66
– –2.3 h
–1.4 h
788.5
948.0
–21**
–2
Adler et al 1998  Tolcapone 100
Placebo
6 wks 69
72
+2.1 h *** –2.0 h*** 810
850
–23**
 −1
Shan et al 2001  Tolcapone 100
Placebo
6 wks 20
20
– –15.8 %*
+1.2 %
795.0
930.0
–7
–2
SWITCH 2006 Tolcapone 100
Entacapone 200
3 wks 150 (tot) +1.6*
+0.8
–– –
Onofrj et al 2001 Tolcapone 100
Entacapone 200
3–7 mo 40 (tot) +15 %*
+8%
–16 %
–7%
Levodopa was sig-
niﬁ  cantly reduced with 
tolcapone: p = 0.01 and 
entacapone: p = 0.05
Rascol 2005 Rasagiline (1 mg/day)
Entacapone (200 mg/
with every levodopa 
dose)
Placebo 
18 wks 231
200
229
+0.85 h
+0.03 h 
(p = 0.0005 
for both)
–1.18 h
–1.2 h
–0.4 h
(p = 0.0001, 
p   0.0001, 
respectively vs 
placebo)
PSG 2005 Rasagiline 0.5 mg/day
Rasagiline 1 mg/day
Placebo
26 wks 164
149
159
+0.51
+0.78*
–0.49
–0.94**
*p   0.05, **p   0.01, ***p   0.001 vs placebo, ****p  =  0.018.Neuropsychiatric Disease and Treatment 2008:4(1) 7
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With regard to safety, dopaminergic-related adverse 
events were the most frequently reported in patients receiv-
ing 200 mg tolcapone tid. Such events (nausea, vomiting, 
dyskinesia, orthostatic complaints, sleep disorders, dystonia, 
confusion, hallucination), are likely a consequence of the 
increase in levodopa concentrations, especially at the begin-
ning of treatment, and are mostly resolved with a reduction 
in levodopa dose. New or worsening dyskinesias were one of 
the most commonly reported dopaminergic-related adverse 
events (25%–62% with tolcapone, 100 mg 3 times daily, 
31%–66% with 200 mg 3 times daily); in any case they were 
not a reason for withdrawal (Deane et al 2004). Some major 
concerns have been raised in the past over the emergence of 
liver toxicity (Watkins 2000).
For this reason, marketing authorization for tolcapone 
was suspended in the EU (late 1998), and labeling was 
tightened in the US. However, suspension of the marketing 
authorization in the EU was later lifted following EMEA 
recommendation (EMEA 2004).
The cause of hepatotoxicity has not been clearly estab-
lished yet, although the current hypothesis suggests a possible 
interference with mithocondrial respiration in hepathocytes, 
by uncoupling oxidative phosphorilation (Borges 2005).
Three cases of fatal fulminant hepatic failure were 
reported with tolcapone in 1998, but it should be noted that 
liver function had not been properly monitored in these 
patients and that the liver dysfunction emerged 2–6 months 
after starting treatment (Olanow 2000). A recent review of 
tolcapone global safety (Valeant Pharmaceuticals Interna-
tional data on ﬁ  le), reported severe hepatocellular injury 
only in 0.04% of patients over the last 7 years, whereas the 
majority of patients experiencing liver toxicity, only showed 
an elevations in liver transaminases without clinical signs 
or symptoms.
In a review of clinical data on 1535 patients (Olanow 
2000), the expert panel also noted that about half the patients 
who continued tolcapone therapy experienced a normaliza-
tion of ALT/AST levels within 1–3 months, whereas patients 
who discontinued tolcapone experienced the normalization 
after just 2–3 weeks. These data are crucial in the evaluation 
of tolcapone’s role in PD therapy; in fact, due to its fast onset 
of action, the identiﬁ  cations of responders can occur early, 
when the liver damage is probably still in a reversible initial 
phase, so non-responders may easily withdraw before liver 
damage is established, whereas responders should be strictly 
monitored, especially in the ﬁ  rst 6 months.
In summary, tolcapone is a useful option for patients 
with idiopathic, ﬂ  uctuating PD patients (Colosimo 1999). 
Clinical practice suggests that tolcapone is more effective 
than entacapone and it can be successfully associated to 
levodopa preparations. In addition it has central activity with 
potential beneﬁ  ts on mood and cognition although this might 
be observed only at doses of 200 mg tid. Data on tolcapone 
effect in patients who have not beneﬁ  ted from entacapone 
(this would be the target population according to EMEA 
guidelines) are still lacking. Randomized trials are warranted 
to demonstrate that adding tolcapone in these individuals is 
indeed beneﬁ  cial.
Conclusions
Current evidence suggests that treatment strategies should 
target both motor and non-motor ﬂ  uctuations, as the latter 
have been often neglected or underestimated in PD. COMT 
inhibitors are beneﬁ  cial because they widen the therapeutic 
window in PD. In addition tolcapone may also have some 
central activity particularly at high dose. Given this evidence 
we suggest that tolcapone should be prescribed to all PD 
patients who continue to complain about motor ﬂ  uctuations 
despite current or previous treatment with entacapone and/or 
MAO-B inhibitors. We believe that a tolcapone trial should 
be considered before other complex and more invasive pro-
cedures are proposed to the patient.
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